FOLH1 and prostate adenocarcinoma: Prostate-specific membrane antigen (PSMA), an integral membrane glycoprotein ectopeptidase with both folate hydrolase and N-acylated, a-linked dipeptidase activities, was first characterized in 1986 by the murine monoclonal antibody 7E11, derived from mice immunized with partially purified cell membrane fractions isolated from the human prostate adenocarcinoma cell line LNCap [1,2,3].